• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Compellis's Collaborator Receives FDA Approval for Phase I Obesity Study

Posted on: Wednesday, 9 January 2008, 09:01 CST

Compellis Pharmaceuticals has announced that its collaborator Pennington Biomedical Research Institute at Louisiana State University has received FDA approval to begin human clinical Phase I obesity studies.

Enrollment for the program will begin in the first quarter of 2008 with an expected completion date in the second half of the year.

CP404 is a calcium channel blocker used in a nasal formulation to block olfactory activity and alter behavior to reduce food intake. Compellis Pharmaceuticals has tested a series of like compounds and believes the effect can be seen in the overall class of calcium channel blockers. The advantage of CP404 is that it is a small molecule that is well tolerated in man and is readily manufactured.

Christopher Adams, CEO of Compellis, said: "The investigational new drug (IND) application approval is a significant milestone achievement for the Compellis/Pennington obesity therapy development effort. Principal investigator Frank Greenway has significant experience with the clinical development of obesity and nutritional therapies. We are excited about entering the Phase I study and look forward to the clinical results of CP404."

Source: Datamonitor

More News in this Category